376 / 412
twice-daily
esomeprazole
treatment
with
a
dose
of
20 mg
for
three
months
demonstrated
a
significantly
greater
im-
provement
in
laryngeal
appearance
and
LPR-related
symp-
toms,
as
reflected
by
the
total
score
differences
of RFS
and
RSI. The most
striking
difference
between
the
study
groups
was
the
significant
reduction
of
posterior
commissure
hy-
pertrophy
in
the
PPI
group.
AUTHOR INFORMATION
From
the Department of Otorhinolaryngology–Head
and Neck Surgery
(Dr
Reichel
and Ms Wiederänders)
and
the
Institute
and Outpatient Clinic
for
Occupational,
Social
and
Environmental Medicine
(Dr
Dressel),
Ludwig
Maximilians
University, Munich,
Germany;
and
the
Department
of
Oto-
laryngology
(Dr
Issing),
The
Freeman
Hospital,
Newcastle
Upon
Tyne,
UK.
Corresponding
author:
Oliver
Reichel, MD, Department
of Otolaryngology–
Head
and
Neck
Surgery,
Klinikum
Großhadern,
Marchioninistraße
15,
81377 Munich, Germany.
address:
Oliver.Reichel@med.uni-muenchen.de.AUTHOR CONTRIBUTIONS
Oliver Reichel
,
study
design,
data
collection;
Holger Dressel
,
data
anal-
ysis,
statistical
analysis;
Katrin Wiederänders
, data
collection;
Wolfgang
J.
Issing
,
study
design.
FINANCIAL DISCLOSURE
This
study was
partially
supported
by
a
grant
from Astra-Zeneca, Wedel,
Germany. AstraZeneca
had
no
involvement
in
the
study
design,
collection,
analysis and interpretation of data; in the writing of the report; or in the
decision to submit the paper for publication.
REFERENCES
1. Altman KW, Stephens RM, Lyttle CS, et al. Changing impact of
gastroesophageal reflux in medical and otolaryngology practice. La-
ryngoscope 2005;115:1145–53.
2. Koufman JA, Aviv JE, Casiano RR, et al. Laryngopharyngeal reflux:
position statement of the Committee on Speech, Voice, and Swallow-
ing Disorders of the American Academy of Otolaryngology–Head and
Neck Surgery. Otolaryngol Head Neck Surg 2002;127:32–5.
3. Ford CN. Evaluation and management of laryngopharyngeal reflux.
JAMA 2005;294:1534–40.
4. Reichel O, Keller J, Rasp G, et al. Efficacy of once-daily esomeprazole
treatment in patients with laryngopharyngeal reflux evaluated by 24-
hour pH monitoring. Otolaryngol Head Neck Surg 2007;136:205–10.
5. Karkos PD, Wilson JA. Empiric treatment of laryngopharyngeal reflux
with proton pump inhibitors: a systemativ review. Laryngoscope 2006;
116:144–8.
6. Havas T, Huang S, Levy M, et al. Posterior pharyngolaryngitis: dou-
ble-blind, randomised placebo-controlled trial of proton pump inhibi-
tor therapy. Aust J Otolaryngol 1999;3:243–6.
7. Steward DL, Wilson KM, Kelly DH, et al. Proton pump inhibitor
therapy for chronic laryngo-pharyngitis: a randomized placebo-control
trial. Otolaryngol Head Neck Surg 2004;131:342–50.
8. Wo JM, Koopman J, Harrell SP, et al. Double-blind, placebo-con-
trolled trial with single-dose pantoprazole for laryngopharyngeal re-
flux. Am J Gastroenterol 2006;101:1972–8.
9. Vaezi MF, Richter JE, Stasney CR, et al. Treatment of chronic pos-
terior laryngitis with esomeprazole. Laryngoscope 2006;116:254–60.
10. Miner P Jr, Katz PO, Chen Y, et al. Gastric acid control with esome-
prazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a
five-way crossover study. Am J Gastroenterol 2003;98:2616–20.
11. Belafsky PC, Postma GN, Koufman JA. The validity and reliability of
the reflux finding score (RFS). Laryngoscope 2001;111:1313–7.
12. Belafsky PC, Postma GN, Koufman JA. Validity and reliability of the
Reflux Symptom Index (RSI). J Voice 2002;16:274–7.
13. Noordzij JP, Khidr A, Evans BA, et al. Evaluation of omeprazole in
the treatment of reflux laryngitis: a prospective, placebo-controlled,
randomized, double-blind study. Laryngoscope 2001;111:2147–51.
14. Koufman JA. The otolaryngologic manifestations of gastroesophageal
reflux disease (GERD): a clinical investigation of 225 patients using
ambulatory 24-hour pH monitoring and an experimental investigation
of the role of acid and pepsin in the development of laryngeal injury.
Laryngoscope 1991;101(suppl 53):1–78.
15. Kamel PL, Hanson D, Kahrilas PJ. Omeprazole for the treatment of
posterior laryngitis. Am J Med 1994;96:321–6.
16. Eherer AJ, Habermann W, Hammer HF, et al. Effect of pantoprazole
on the course of reflux-associated laryngitis: a placebo-controlled
double-blind crossover study. Scand J Gastroenterol 2003;38:462–7.
17. Belafsky PC, Postma GN, Koufman JA. Laryngopharyngeal reflux
symptoms improve before changes in physical findings. Laryngoscope
2001;111:979–81.
18. El-Serag HB, Lee P, Buchner A, et al. Lansoprazole treatment of
patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Am J Gastroenterol 2001;96:979–83.
19. Book DT, Rhee JS, Toohill RJ, et al. Perspectives in laryngopharyn-
geal reflux: an international survey. Laryngoscope 2002;112:1399–
406.
20. DelGaudio JM, Waring JP. Empiric esomeprazole in the treatment of
laryngopharyngeal reflux. Laryngoscope 2003;113:598–601.
Otolaryngology–Head and Neck Surgery, Vol 139, No 3, September 2008
151